Fate Therapeutics
Clinical trials sponsored by Fate Therapeutics, explained in plain language.
-
First human trial tests new cell therapy for devastating autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing the safety of an experimental cell therapy called FT819 for four serious autoimmune diseases: lupus, vasculitis, myositis, and scleroderma. Researchers will give FT819 to 244 participants aged 12-70 who have moderate to severe disease that hasn't…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC
-
New 'Off-the-Shelf' cancer therapy enters human testing for multiple advanced cancers
Disease control Recruiting nowThis early-stage study is testing FT836, a new type of 'off-the-shelf' CAR T-cell therapy, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how well the body tolerates FT836, which is given al…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New 'Off-the-Shelf' cell therapy trial opens for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called FT825/ONO-8250 in people with advanced solid tumors that have stopped responding to standard treatments. The therapy involves modifying a patient's immune cells (T-cells) in a lab to better target and fight cance…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC